Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 3

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin

Authors Ramana RK, Lewis BE

Published 6 June 2008 Volume 2008:4(3) Pages 493—505

DOI https://doi.org/10.2147/VHRM.S2455


Ravi K Ramana, Bruce E Lewis

Division of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA

Abstract: Previously, indirect thrombin inhibitors such as unfractionated heparin or low-molecular-weight heparin were used as a standard anticoagulation during percutaneous coronary intervention to prevent procedural thrombotic complications but at a risk of hemorrhagic complications. More recently, bivalirudin, a member of the direct thrombin inhibitor class, has been shown to have 1) predictable pharmacokinetics, 2) ability to inhibit free- and clot-bound thrombin, 3) no properties of platelet activation, 4) avoidance of heparin-induced thrombocytopenia, and 5) a significant reduction of bleeding without a reduction in thrombotic or ischemic endpoints compared to heparin and glycoprotein IIbIIIa inhibitors when used in patients presenting with acute coronary syndrome who are planned for an invasive treatment strategy.

Keywords: bivalirudin, coronary intervention, direct thrombin inhibitor, acute coronary syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]